Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa

Katherine J. Wert, Javier Sancho-Pelluz, Stephen H. Tsang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Deficiencies in rod-specific cyclic guanosinemonophosphate (cGMP)phosphodiesterase-6 (PDE6) are the third most common cause of autosomal recessive retinitis pigmentosa (RP). Previously, viral gene therapy approaches on pre-clinical models with mutations in PDE6 have demonstrated that the photoreceptor cell survivalandvisual functioncanberescuedwhenthegenetherapy virus is delivered into the subretinalspace before the onset of disease. However, no studies have currently been published that analyze rescue effects after disease onset, a time when human RP patients are diagnosed by a clinician and would receive the treatment. We utilized the AAV2/8(Y733F)-Rho-Pde6α gene therapy virus and injected it into a pre-clinical model of RP with a mutation within the alpha subunit of PDE6: Pde6αD670G. These mice were previously shown to have long-term photoreceptor cell rescue when this gene therapy virus was delivered before the onset of disease. Now, we have determined that subretinal transduction of this rod-specific transgene at post-natal day (P) 21, when approximately half of the photoreceptor cells have undergone degeneration, is more efficient in rescuing cone than rod photoreceptor function long term. Therefore, AAV2/8(Y733F)-Rho-Pde6α is an effective gene therapy treatment that can be utilized in the clinical setting, in human patients who have lost portions of their peripheral visual field and are in the mid-stage of disease when they first present to an eye-care professional.

Original languageEnglish (US)
Pages (from-to)514-523
Number of pages10
JournalHuman molecular genetics
Volume23
Issue number2
DOIs
StatePublished - Jan 2014
Externally publishedYes

Fingerprint

Type 6 Cyclic Nucleotide Phosphodiesterases
Retinitis Pigmentosa
Genetic Therapy
Photoreceptor Cells
Viruses
Retinal Cone Photoreceptor Cells
Retinal Rod Photoreceptor Cells
Mutation
Viral Genes
Therapeutics
Visual Fields
Transgenes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa. / Wert, Katherine J.; Sancho-Pelluz, Javier; Tsang, Stephen H.

In: Human molecular genetics, Vol. 23, No. 2, 01.2014, p. 514-523.

Research output: Contribution to journalArticle

@article{c4c833e7c8534971ba06b2bd469ed5e1,
title = "Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa",
abstract = "Deficiencies in rod-specific cyclic guanosinemonophosphate (cGMP)phosphodiesterase-6 (PDE6) are the third most common cause of autosomal recessive retinitis pigmentosa (RP). Previously, viral gene therapy approaches on pre-clinical models with mutations in PDE6 have demonstrated that the photoreceptor cell survivalandvisual functioncanberescuedwhenthegenetherapy virus is delivered into the subretinalspace before the onset of disease. However, no studies have currently been published that analyze rescue effects after disease onset, a time when human RP patients are diagnosed by a clinician and would receive the treatment. We utilized the AAV2/8(Y733F)-Rho-Pde6α gene therapy virus and injected it into a pre-clinical model of RP with a mutation within the alpha subunit of PDE6: Pde6αD670G. These mice were previously shown to have long-term photoreceptor cell rescue when this gene therapy virus was delivered before the onset of disease. Now, we have determined that subretinal transduction of this rod-specific transgene at post-natal day (P) 21, when approximately half of the photoreceptor cells have undergone degeneration, is more efficient in rescuing cone than rod photoreceptor function long term. Therefore, AAV2/8(Y733F)-Rho-Pde6α is an effective gene therapy treatment that can be utilized in the clinical setting, in human patients who have lost portions of their peripheral visual field and are in the mid-stage of disease when they first present to an eye-care professional.",
author = "Wert, {Katherine J.} and Javier Sancho-Pelluz and Tsang, {Stephen H.}",
year = "2014",
month = "1",
doi = "10.1093/hmg/ddt452",
language = "English (US)",
volume = "23",
pages = "514--523",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa

AU - Wert, Katherine J.

AU - Sancho-Pelluz, Javier

AU - Tsang, Stephen H.

PY - 2014/1

Y1 - 2014/1

N2 - Deficiencies in rod-specific cyclic guanosinemonophosphate (cGMP)phosphodiesterase-6 (PDE6) are the third most common cause of autosomal recessive retinitis pigmentosa (RP). Previously, viral gene therapy approaches on pre-clinical models with mutations in PDE6 have demonstrated that the photoreceptor cell survivalandvisual functioncanberescuedwhenthegenetherapy virus is delivered into the subretinalspace before the onset of disease. However, no studies have currently been published that analyze rescue effects after disease onset, a time when human RP patients are diagnosed by a clinician and would receive the treatment. We utilized the AAV2/8(Y733F)-Rho-Pde6α gene therapy virus and injected it into a pre-clinical model of RP with a mutation within the alpha subunit of PDE6: Pde6αD670G. These mice were previously shown to have long-term photoreceptor cell rescue when this gene therapy virus was delivered before the onset of disease. Now, we have determined that subretinal transduction of this rod-specific transgene at post-natal day (P) 21, when approximately half of the photoreceptor cells have undergone degeneration, is more efficient in rescuing cone than rod photoreceptor function long term. Therefore, AAV2/8(Y733F)-Rho-Pde6α is an effective gene therapy treatment that can be utilized in the clinical setting, in human patients who have lost portions of their peripheral visual field and are in the mid-stage of disease when they first present to an eye-care professional.

AB - Deficiencies in rod-specific cyclic guanosinemonophosphate (cGMP)phosphodiesterase-6 (PDE6) are the third most common cause of autosomal recessive retinitis pigmentosa (RP). Previously, viral gene therapy approaches on pre-clinical models with mutations in PDE6 have demonstrated that the photoreceptor cell survivalandvisual functioncanberescuedwhenthegenetherapy virus is delivered into the subretinalspace before the onset of disease. However, no studies have currently been published that analyze rescue effects after disease onset, a time when human RP patients are diagnosed by a clinician and would receive the treatment. We utilized the AAV2/8(Y733F)-Rho-Pde6α gene therapy virus and injected it into a pre-clinical model of RP with a mutation within the alpha subunit of PDE6: Pde6αD670G. These mice were previously shown to have long-term photoreceptor cell rescue when this gene therapy virus was delivered before the onset of disease. Now, we have determined that subretinal transduction of this rod-specific transgene at post-natal day (P) 21, when approximately half of the photoreceptor cells have undergone degeneration, is more efficient in rescuing cone than rod photoreceptor function long term. Therefore, AAV2/8(Y733F)-Rho-Pde6α is an effective gene therapy treatment that can be utilized in the clinical setting, in human patients who have lost portions of their peripheral visual field and are in the mid-stage of disease when they first present to an eye-care professional.

UR - http://www.scopus.com/inward/record.url?scp=84898826569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898826569&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddt452

DO - 10.1093/hmg/ddt452

M3 - Article

C2 - 24101599

AN - SCOPUS:84898826569

VL - 23

SP - 514

EP - 523

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 2

ER -